Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On Apr 29, we retained Varian Medical Systems, Inc. (VAR - Analyst Report) at Neutral after the company reported results for the second quarter fiscal 2013.

Why the Reiteration?

On April 24, Varian reported net earnings of $1.04 per share which beat the Zacks Consensus Estimate of $1.01 per share.

Revenues in the fiscal second quarter increased 7% year over year to $768.4 million, beating the Zacks Consensus Estimate of $765 million. Order backlog rose 4% year over year to $2,752.6 million at the end of the reported quarter. Net orders dropped 14.7% year over year to $735.8 million.

Revenues from Oncology Systems increased 3% year over year to $581.8 million in the fiscal second quarter. Net orders for the segment dropped 2% (9% drop in North America partly offset by a 4% rise ex-North America) to $555 million.

Revenues for X-Ray Products segment in the fiscal second quarter came in at $140.4 million, up 14% year over year. Revenues from the Other category rose about 43.9% from the year-ago quarter to $46.2 million in the reported quarter.

Following the release of the fiscal second quarter results, the Zacks Consensus Estimate for fiscal 2013 has remained stagnant at $4.11 over the last 7 days. The Zacks Consensus Estimate for fiscal 2014 has declined 1.3% to $4.59 during the same timeframe.

Moving ahead, Varian continues to expect revenues to grow by about 8% for fiscal 2013. Net earnings for fiscal 2013 remain unchanged in the band of $4.09 to $4.14 per share. For third-quarter fiscal 2013, the company envisions sales to grow roughly 7% year over year. Varian expects net earnings in the range of 98 cents to $1.02 per share for the fiscal third quarter.

Med-Tech Stocks that Warrant a Look

Varian carries a Zacks Rank #3 (Buy). NuVasive, Inc. (NUVA - Snapshot Report) carries a Zacks Rank #1 (Strong Buy). Abiomed, Inc. (ABMD - Analyst Report) and The Cooper Companies Inc. (COO - Analyst Report) each carry a Zacks Rank #2 (Buy) and are expected to do well.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%